BMN 250

Drug Profile

BMN 250

Alternative Names: Alpha-N-acetyglucosaminidase-insulin-like-growth-factor-2 fusion protein; BMN250; NAGLU-IGF2 fusion protein

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Acetylglucosaminidases; Recombinant fusion proteins
  • Mechanism of Action Alpha N acetyl D glucosaminidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 15 Mar 2018 Biomarin Pharmaceuticals plans a phase II trial for Mucopolysaccharidosis III (In children) in Argentina, Australia, Colombia, Germany, Spain, Taiwan, Turkey, United Kingdom and USA (EudraCT-2017-003083-13)
  • 22 Feb 2018 Updated efficacy data from a phase I/II trial in Mucopolysaccharidosis III released by BioMarin Pharmaceutical
  • 06 Sep 2017 Interim efficacy and adverse data from a phase I/II trial in Mucopolysaccharidosis III released by BioMarin Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top